Introduction: Parkinson’s disease is affecting millions of people worldwide. The prevalence
of Parkinson’s disease is 0.3% globally, rising to 1% in more than 60 years of age and 4% in
more than 80 years of age and the figures are thought to be doubled by 2030. Thus, there is a great
need to identify novel therapeutic strategies or candidate drug molecule which can rescue neuronal
degeneration. β -asarone has the potential to act as a neuroprotective agent but regarding its role in
Parkinson’s disease, very few reports are available. Thus, this study was undertaken to unlock the potential
of β-asarone against Parkinson’s disease.
Material and Methods: The Absorption, Distribution, Metabolism, and Excretion (ADME) analysis
has been done by using Swiss ADME Predictor. The interactions of β-asarone with dopaminergic receptors
were investigated by Glide Program 5.0. The crystal structures of dopamine receptors were retrieved
from Research Collaboratory for Structural Bioinformatics- Protein Data Bank (RCSB-PDB).
The structure of β-asarone was drawn in Chem Draw Ultra 7.0.1. Finally, the toxicity of β-asarone has
been predicted by using online web-servers like Lazar and Protox.
Results and Discussion: The ADME data of current investigation has shown good oral bioavailability
of β-asarone. It also showed a good binding affinity towards dopaminergic receptors. Further, it was
found to be interacting through hydrogen bond with different amino acid residues of D2 and D3 receptors.
However, β-asarone was predicted to be toxic in various species of rodents, as per the results of
toxicity online web servers.
Conclusion: Based on the current finding from ADME and docking studies, these preliminary results
may act as effective precursor tool for the development of β-asarone as a promising anti-Parkinson
agent. However, furthermore experimental validation using in-vitro & in-vivo studies is needed to explore
their therapeutic andtoxic effects.